| Literature DB >> 35056144 |
Piret Saar-Reismaa1, Olga Bragina1,2, Maria Kuhtinskaja1, Indrek Reile3, Pille-Riin Laanet1, Maria Kulp1, Merike Vaher1.
Abstract
Lyme disease (LD) is a tick-borne bacterial disease that is caused by Borrelia burgdorferi. Although acute LD is treated with antibiotics, it can develop into relapsing chronic form caused by latent forms of B. burgdorferi. This leads to the search for phytochemicals against resistant LD. Therefore, this study aimed to evaluate the activity of Dipsacus fullonum L. leaves extract (DE) and its fractions against stationary phase B. burgdorferi in vitro. DE showed high activity against stationary phase B. burgdorferi (residual viability 19.8 ± 4.7%); however, it exhibited a noticeable cytotoxicity on NIH cells (viability 20.2 ± 5.2%). The iridoid-glycoside fraction showed a remarkable anti-Borrelia effect and reduced cytotoxicity. The iridoid-glycoside fraction was, therefore, further purified and showed to contain two main bioactives-sylvestrosides III and IV, that showed a considerable anti-Borrelia activity being the least toxic to murine fibroblast NIH/3T3 cells. Moreover, the concentration of sylvestrosides was about 15% of DE, endorsing the feasibility of purification of the compounds from D. fullonum L. leaves.Entities:
Keywords: Borrelia burgdorferi; Dipsacus fullonum L.; antibacterial activity; bis-iridoids; cytotoxicity; sylvestrosides
Year: 2022 PMID: 35056144 PMCID: PMC8779505 DOI: 10.3390/ph15010087
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Dipsacus fullonum L. harvested from Saaremaa, Estonia, 2017.
Figure 2Chromatogram of DE, with selected peaks for quantification. The results of identification are presented in Table 1. Peak 21—internal standard, bicalutamide, 40.0 mg/L.
Identification and concentrations of DE compounds.
| Peak | Compound | Tret, Min | λmax, nm | MS, | MS/MS, | Conc., mg/L |
|---|---|---|---|---|---|---|
| 1 | Chlorogenic acid | 4.7 | 245; 325 | 353 | 191 | 47.8 ± 2.7 |
| 2 | Loganic acid | 5.8 | 230 | 375 | 213; 169 | 14.6 ± 2.1 |
| 3 | Luteolin derivative | 9.3 | 270; 350 | 609 | 447; 325 | 0.8 ± 0.3 |
| 4 | Loganin | 9.5 | 238 | 389 | 227; 209 | 13.6 ± 0.7 |
| 5 | Loganic acid ethyl ester | 9.8 | 245 | 403 | 395; 357 | 6.0 ± 0.5 |
| 6 | Saponarin | 10.4 | 270; 335 | 593 | 311; 431; 473 | 48.1 ± 6.1 |
| 7 | Isoorientin | 10.7 | 347 | 447 | 557; 327; 429 | 16.3 ± 2.1 |
| 8 | Dichlorogenic acid isomer | 11.1 | 325 | 515 | 353; 191 | 39.7 ± 1.9 |
| 9 | Dichlorogenic acid isomer | 11.6 | 325 | 515 | 353; 173; 203 | 3.6 ± 3.2 |
| 10 | Isovitexin | 12.0 | 268; 340 | 431 | 311; 341; 413 | 11.7 ± 0.5 |
| 11 | bis-Iridoid glycoside | 12.9 | 238 | 541 | – | 4.4 ± 0.8 |
| 12 | bis-Iridoid glycoside | 13.5 | 240 | 585 | 373 | 0.8 ± 0.3 |
| 13 | bis-Iridoid glycoside | 13.8 | 240 | 583 | 513; 459 | 1.0 ± 0.6 |
| 14 | bis-Iridoid glycoside | 14.1 | 240 | 585 | 373 | 5.0 ± 0.7 |
| 15 | bis-Iridoid glycoside | 14.7 | 240 | 585 | 373 | 4.8 ± 0.9 |
| 16 | bis-Iridoid glycoside | 15.1 | 240 | 585 | 373 | 2.9 ± 0.4 |
| 17 | bis-Iridoid glycoside | 15.6 | 240 | 583 | 373 | 4.9 ± 1.6 |
| 18 | Sylvestrosides III and IV | 16.2 | 240 | 583 | 373 | 42.5 ± 4.7 |
| 19 | bis-Iridoid glycoside | 16.5 | 240 | 583 | 373 | 0.9 ± 0.2 |
| 20 | bis-Iridoid glycoside | 16.8 | 240 | 583 | 373 | 10.5 ± 0.1 |
| 21 | Bicalutamide (IS) | 23.3 | 215; 270 | 429 | 255; 183 | 500 |
Preliminary screening for activity against stationary phase B. burgdorferi.
| NP Number | Main Constituents | Activity |
|---|---|---|
| NP1 | Chlorophylls | − |
| NP2 | bis-Iridoids ( | + |
| NP3 | Iridoids—loganin, loganic acid ethyl ester | − |
| NP4 | Loganin derivatives | − |
| NP5 | Loganic acid | + |
| NP6 | Isovitexin, saponarin, isoorientin | + |
| NP7 | Saponarin, isoorientin, 2 chlorogenic acid derivatives | + |
| NP8 | Saponarin, isoorientin, chlorogenic acid | + |
Effect of DE and its fractions on the seven-day old stationary phase B. burgdorferi.
| Sample | Gross Conc., mg/L | Residual Viability, % |
|---|---|---|
| DE | 305.5 ± 24.5 | 19.8 ± 4.7 |
| NP2 | 295.4 ± 12.1 | 54.3 ± 10.4 |
| NP5 | 332.8 ± 34.7 | 29.8 ± 7.8 |
| NP7 | 340.2 ± 14.5 | 23.4 ± 15.8 |
| DM | 308.6 ± 20.2 | 40.2 ± 9.1 |
| NP2-RP | 300.2 ± 8.9 | 64.5 ± 14.9 |
| Dox., Cefo., Dap. * | 22.2; 33.4; 80.1 | 24.9 ± 7.4 |
* Abbreviations: conc.—concentration; Dox.—doxycycline; Cefo.—cefoperazone; Dap.—daptomycin.
Figure 3Cytotoxic effect of DE and its fractions on NIH 3T3 cells assessed by WST1 assay after 48 h. The experiments were run triplicate. The graphs represent as mean ± SD. Cells treated with 60% EtOH were normalized to 100% as control; p < 0.001 as ***, p < 0.0001 as ****.